Your browser doesn't support javascript.
loading
Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A.
Mahajerin, Arash; Faghmous, Imi; Kuebler, Peter; Howard, Monet; Xu, Tao; Flores, Carlos; Chang, Tiffany; Nissen, Francis.
Afiliação
  • Mahajerin A; Divisions of Pediatric Hematology and Oncology, University of California, Irvine and CHOC Children's Specialists, Irvine, CA 92868, USA.
  • Faghmous I; Department of Real-World Data Oncology-Hematology, F Hoffmann-La Roche Ltd., Basel, CH-4070, Switzerland.
  • Kuebler P; Current affiliation: Faculty of Health, Medicine and Life Sciences, University of Maastricht, Maastricht, P Debyeplein15, DEB15, 6229 HA, The Netherlands.
  • Howard M; Department of Personalized Healthcare Safety Interface, Genentech, Inc., South San Francisco, CA 94080, USA.
  • Xu T; Department of Clinical Safety, F Hoffmann-La Roche Ltd., Mississauga, ON, L5N 5M8, Canada.
  • Flores C; Department of Personalized Healthcare Product Development, F Hoffmann-La Roche Ltd., Basel, CH-4070, Switzerland.
  • Chang T; Department of Evidence Strategy, Genesis Research, Hoboken, NJ 07030, USA.
  • Nissen F; Department of Personalized Healthcare Safety Interface, Genentech, Inc., South San Francisco, CA 94080, USA.
J Comp Eff Res ; 11(10): 717-728, 2022 07.
Article em En | MEDLINE | ID: mdl-35535702
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemostáticos / Anticorpos Biespecíficos / Hemofilia A Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemostáticos / Anticorpos Biespecíficos / Hemofilia A Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article